CU Boulder News & Events

MAPK and mTORC1 signaling converge to drive cyclin D1 protein production to enable cell cycle reentry in melanoma persister cells

[button url="http://chem.colorado.edu/" color="blue"]Department of Chemistry and Biochemistry[/button] [button url="www.colorado.edu" color="blue"]University of ...
Business Wire

Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
ascopubs.org

After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor–Positive Metastatic Breast Cancer

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Cure Today

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial will determine ...
Morningstar

Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program

Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program Circle Pharma, Inc., a clinical-stage ...